Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant

Journal of Medical Toxicology

Volumn 7, Issue 4, 2011, Pages 281-287

  Ganetsky, Michael ^a   Babu, Kavita M ^b   Salhanick, Steven D ^a   Brown, Robert S ^a   Boyer, Edward W ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Dabigatran; Direct thrombin inhibitors; Hemodialysis; Pradaxa

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIINFLAMMATORY AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DABIGATRAN ETEXILATE; ENOXAPARIN; FRESH FROZEN PLASMA; GLYCOPROTEIN P; HIRUDIN; HIRULOG; NONSTEROID ANTIINFLAMMATORY AGENT; PROTHROMBIN COMPLEX; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; VERAPAMIL; WARFARIN;

BLEEDING; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME METABOLISM; ERYTHROCYTE TRANSFUSION; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; NONHUMAN; RAT; REVIEW; STROKE; THROMBOCYTE AGGREGATION; UNITED STATES;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; PARTIAL THROMBOPLASTIN TIME; RENAL DIALYSIS;

EID: 82555172355     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-011-0178-y     Document Type: Review

References (40)

1. Wann LS, Curtis AB, Ellenbogen KA et al (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 57(11): 1330-1337.
2. Melnikova I (2009) The anticoagulants market. Nat Rev Drug Discov 8(5): 353-354.
3. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45(9): 1757-1766.
4. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98(1): 155-162.
5. Di Nisio M, Middeldorp S, Buller HR (2005) Direct thrombin inhibitors. N Engl J Med 353(10): 1028-1040.
6. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407(6801): 258-264.
7. Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD (1987) Thrombin chemotactic stimulation of HL-60 cells: studies on thrombin responsiveness as a function of differentiation. J Cell Physiol 131(2): 255-261.
8. Griffith MJ (1982) Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin. J Biol Chem 257(13): 7360-7365.
9. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD (1980) The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 255(21): 10081-10090.
10. Tulinsky A (1996) Molecular interactions of thrombin. Semin Thromb Hemost 22(2): 117-124.
11. Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI (2001) Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276(24): 20959-20965.
12. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86(2): 385-391.
13. Weitz JI, Leslie B, Hudoba M (1998) Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97(6): 544-552.
14. Xiao Z, Theroux P (1998) Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97(3): 251-256.
15. Freedman MD (1992) Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 32(3): 196-209.
16. Wells PS, Holbrook AM, Crowther NR, Hirsh J (1994) Interactions of warfarin with drugs and food. Ann Intern Med 121(9): 676-683.
17. Arnason T, Wells PS, van Walraven C, Forster AJ (2006) Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 118(2): 253-262.
18. Schwarz UI, Ritchie MD, Bradford Y et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358(10): 999-1008.
19. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3): 292-303.
20. Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47(5): 285-295.
21. van Ryn J, Stangier J, Haertter S et al (2011) Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6): 1116-1127.
22. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2): 386-399.
23. Pradaxa [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT; March 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s004lbl.pdf. Accessed 4 Aug 2011.
24. Stangier J, Stahle H, Rathgen K. No interaction of the oral direct thrombin dabigatran etexilate and digoxin abstract no. P-W-672; online. Available from URL: http://isth2007.abstractsondemand.com/ Accessed 30 June 2011.
25. Stangier J, Stahle H, Rathgen K, Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47(1): 47-59.
26. Stangier J, Rathgen K, Stahle H, Mazur D (2011) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4): 259-268.
27. Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K (2008) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48(12): 1411-1419.
28. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12): 1139-1151.
29. Beasley BN, Unger EF, Temple R (2011) Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 364(19): 1788-1790.
30. Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24): 2342-2352.
31. Eriksson BI, Dahl OE, Huo MH et al (2011) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 105(4): 721-729.
32. Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11): 2178-2185.
33. Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591): 949-956.
34. The RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24(1): 1-9.
35. Eriksson BI, Dahl OE, Buller HR et al (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3(1): 103-111.
36. Aniara. http://dabigatrantesting.com/. Accessed 17 May 2011.
37. Freyburger G, Macouillard G, Labrouche S, Sztark F (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127(5): 457-465.
38. Crowther MA, Warkentin TE (2009) Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 7(Suppl 1): 107-110.
39. Oh JJ, Akers WS, Lewis D, Ramaiah C, Flynn JD (2006) Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 26(4): 569-577.
40. Davenport A (2008) Practical guidance for dialyzing a hemodialysis patient following acute brain injury. Hemodial Int 12(3): 307-312.